Substance-related harm remains a serious concern across Vermont. The Vermont Department of Health recorded 170 fatal drug overdoses among state residents in 2025. Although that preliminary total was lower than the previous year, every number represents a person, a family, and a community affected by loss.
Substance use disorders also rarely exist in isolation. Depression, anxiety, trauma, chronic stress, and other psychiatric concerns may overlap with substance use, influence one another, and complicate recovery. That does not mean every person uses substances to manage emotional pain, but it does mean effective care often needs to address more than one condition at a time.
At Taconic Psychiatry in Manchester, we provide integrative psychiatric care for people with a range of mental health and substance-use concerns. Ketamine may be considered for selected patients, but its use for any substance use disorder is off-label and investigational. It is not a stand-alone addiction treatment, a substitute for established care, or appropriate for everyone.
Addiction and Mental Health Often Overlap
Substance use and psychiatric symptoms can interact in several ways. A mental health condition may precede substance use, substance use may contribute to psychiatric symptoms, or both may arise from shared biological, social, environmental, and personal risk factors.
For example, depression or trauma symptoms may make recovery harder to sustain. At the same time, repeated substance use, withdrawal, disrupted sleep, unstable relationships, and health consequences can intensify anxiety, low mood, irritability, or hopelessness.
This is why our integrative psychiatry approach looks at the full clinical picture. We consider psychiatric symptoms, substance-use history, medical health, medications, sleep, relationships, stress, support systems, previous treatment, and the patient’s current goals.
Treating co-occurring concerns together can be more useful than viewing them as unrelated problems. It also helps us determine whether ketamine has any reasonable place in the plan—or whether another form of care should take priority.
Our article on what integrative psychiatry means at Taconic Psychiatry explains how we bring biological, psychological, relational, and lifestyle factors into treatment planning.
What the Ketamine Research Actually Shows
Research into ketamine for substance use disorders is still at an early stage. The published studies vary considerably in the substances examined, patient populations, ketamine routes, doses, psychological interventions, and outcomes measured.
Most studies have been small proof-of-concept or phase 2 trials. Several have paired intravenous ketamine with a structured behavioral or psychotherapeutic intervention rather than testing ketamine by itself.
That distinction matters. Results from a carefully controlled research protocol cannot automatically be applied to every patient, every substance use disorder, or every form of ketamine treatment. The findings are best understood as reasons for further study—not proof that ketamine is an established addiction treatment.
The evidence is also uneven. Alcohol use disorder has received more research attention than many other substance use disorders. There are also preliminary findings involving cocaine use disorder. Evidence for opioid use disorder remains especially limited, and ketamine must not be presented as a replacement for established medications or addiction-specialty care.
For a broader look at what ketamine therapy involves, our post on A First-Time Guide to Ketamine Therapy offers helpful background for patients who are new to the topic.
Alcohol Use Disorder: Encouraging Signals With Important Limits
One area of research examines whether ketamine may affect learned associations involving alcohol.
A 2019 study involved people who engaged in harmful drinking. Researchers used a specific memory-reactivation procedure before administering intravenous ketamine. Participants who received ketamine immediately after alcohol-related memory retrieval showed reductions in alcohol’s reinforcing effects and in drinking over follow-up.
This was not a standard clinical ketamine protocol, however. The study examined a highly specific experimental procedure in hazardous drinkers. It did not establish that a routine ketamine infusion or injection prevents relapse in people with alcohol use disorder.
A later phase 2 trial studied 96 recently detoxified adults with severe alcohol use disorder. Participants received three intravenous ketamine or saline infusions, combined with either relapse-prevention therapy or alcohol education.
The ketamine groups reported a greater percentage of abstinent days during six months of follow-up. However, the researchers did not find a statistically significant difference in the rate of relapse between ketamine and placebo groups.
These findings are worth studying further, but they do not support promising that ketamine will eliminate cravings, prevent relapse, or produce lasting recovery.
Cocaine Use Disorder: A Small Controlled Trial
A randomized clinical trial involving 55 adults with cocaine dependence compared a single intravenous ketamine infusion with an active control medication. Both groups also began a five-week mindfulness-based relapse-prevention program.
Participants assigned to ketamine were more likely to remain abstinent near the end of the trial and had a longer time before cocaine use or study dropout. The findings were promising, but the study was small and involved an intensive research setting that included hospitalization and structured behavioral treatment.
It therefore cannot tell us whether ketamine alone would produce the same outcome, whether the effects apply to broader patient populations, or whether an IM protocol would have comparable results.
Larger and longer trials are needed before ketamine can be considered an established treatment for cocaine use disorder.
Why Treatment Route and Clinical Context Matter
Most contemporary trials involving alcohol or cocaine use disorders have studied intravenous ketamine. Taconic Psychiatry’s in-office service uses intramuscular ketamine.
IV and IM administration are not interchangeable. They differ in absorption, dosing control, research history, and treatment experience. Findings from an IV study do not prove that IM ketamine will produce the same addiction-related outcomes.
Psychological support also matters when interpreting the evidence. Several studies paired ketamine with relapse-prevention therapy, mindfulness-based behavioral treatment, or a memory-reactivation procedure. The results cannot be attributed confidently to medication alone.
This fits our broader clinical philosophy: ketamine should not be separated from evaluation, preparation, psychiatric follow-up, and appropriate psychological or addiction-focused care.
How We Evaluate Ketamine When Substance Use Is Part of the Picture
We do not assume that a history of substance use automatically qualifies or disqualifies someone from ketamine treatment. We begin with a detailed, individualized evaluation.
That assessment may include:
- The substances involved and current pattern of use
- The presence of intoxication, withdrawal, or recent instability
- Previous treatment and recovery history
- Co-occurring psychiatric symptoms
- Medical conditions and current medications
- Past misuse of prescribed or nonprescribed substances
- Available support and recovery resources
- The patient’s understanding of ketamine’s risks and limitations
- Whether another treatment should take priority
We also consider why ketamine is being requested. Some patients are primarily seeking help for a co-occurring psychiatric condition. Others may have heard that ketamine treats addiction directly. Those situations require different conversations and may lead to different recommendations.
Our conditions treated at Taconic Psychiatry provide a starting point, but a condition listed on our website does not mean that every patient with that diagnosis is an appropriate ketamine candidate.
Ketamine Has Its Own Misuse Risks
The possibility of using ketamine in people with substance-use histories creates an important clinical tension: researchers are studying it as a potential treatment, yet ketamine itself can be misused.
Repeated, uncontrolled use has been associated with tolerance, cravings, continued use despite harm, cognitive concerns, urinary tract injury, and other adverse effects. Combining ketamine with other substances can create additional risks.
A history of substance use therefore calls for careful assessment rather than promotional reassurance. Depending on the patient, we may need closer monitoring, communication with other providers, changes to the proposed treatment setting, or a recommendation against ketamine.
We discuss these concerns openly. A patient should understand both the emerging research and the reasons the treatment may not be appropriate for their particular circumstances.
For additional background, our discussion of PTSD and ketamine within integrative care explains why trauma symptoms, patient selection, and the broader treatment plan all require individualized consideration.
Ketamine Does Not Replace Established Addiction Treatment
Substance use disorders have evidence-based treatments that should not be delayed or replaced by an experimental ketamine approach.
For opioid use disorder, established medications include buprenorphine, methadone, and naltrexone. These medications can reduce opioid use, improve retention in treatment, and lower overdose risk. Ketamine has not been established as an alternative to them.
Depending on the substance and the individual, treatment may also involve withdrawal management, addiction medicine, psychotherapy, peer recovery support, harm-reduction services, residential or intensive outpatient care, and treatment for co-occurring medical or psychiatric conditions.
Our primary role is integrative psychiatric care. When a patient needs detoxification, medication treatment for opioid use disorder, or a dedicated addiction program, we may recommend or coordinate with an appropriate addiction specialist or treatment service.
Ketamine, when considered at all, should support a responsible plan rather than compete with proven care.
Barriers We See in Substance-Use Care
Stigma Can Make Honest Assessment Harder
Patients may worry that disclosing current or past substance use will lead to judgment or an automatic denial of care. That fear can make it harder for clinicians to assess risk accurately.
We aim to meet honest disclosure with compassion and clinical curiosity. Complete information helps us make a safer recommendation. Withholding substance use, medication, or relapse information can create serious risks during treatment.
Hope Can Turn Preliminary Evidence Into Certainty
People who have struggled through repeated relapses or unsuccessful treatments are understandably interested in something new. Early research can sound more conclusive in headlines than it is in the underlying studies.
We want to preserve hope without overstating the evidence. Ketamine may eventually have a defined role in treating certain substance use disorders, particularly when paired with structured psychological care. At present, that role remains under investigation.
Our post on how safe ketamine therapy is addresses common questions about risk and suitability in plain language.
Rural Access Can Fragment Care
In Vermont, psychiatric care, addiction medicine, psychotherapy, and recovery support may be located far apart. Travel and limited local availability can make coordination difficult.
Our integrative model can help address psychiatric and psychological concerns within one practice, but it does not replace every level of addiction care. We work to identify which services belong within our role and which require collaboration or referral.
Common Questions About Ketamine and Addiction Recovery
Can ketamine treat addiction directly?
Ketamine is being studied as a possible intervention for certain substance use disorders, particularly alcohol and cocaine use disorders. Small trials have reported encouraging findings, but the evidence is not yet sufficient to consider ketamine an established addiction treatment. Its use for a substance use disorder is off-label and investigational.
Does ketamine reduce cravings?
Some studies have reported changes in craving or responses to substance-related cues. Those results came from specific research protocols and have not been established across substances, routes, or patient populations. We cannot promise that ketamine will reduce cravings for an individual patient.
Is ketamine safe for someone with a substance-use history?
A substance-use history does not produce one universal answer. Ketamine has misuse and dependence potential, so careful evaluation and monitoring are especially important. Current use, withdrawal risk, previous misuse, medical history, psychiatric stability, recovery supports, and the proposed treatment setting all affect the decision.
Does Taconic Psychiatry replace an addiction treatment program?
No. Our primary focus is integrative psychiatric care, including assessment and treatment of co-occurring mental health concerns. Patients who need withdrawal management, medications for opioid use disorder, residential treatment, or another dedicated addiction service should receive care from an appropriately qualified program or clinician. We may coordinate our psychiatric care with those services when appropriate.
Must I already be in recovery before ketamine is considered?
We assess each patient individually rather than applying a single rule based only on a label. Active intoxication, withdrawal, uncontrolled use, or other instability may make ketamine unsafe or inappropriate. An evaluation is necessary to determine whether ketamine should be considered, postponed, or excluded from the plan.
Is ketamine for addiction covered by insurance?
Taconic Psychiatry does not accept insurance, including Medicare or Medicaid. Patients pay at the time of service, and we may provide documentation for possible out-of-network reimbursement. Reimbursement is determined by the individual insurer and is not guaranteed. Off-label ketamine treatment is often not covered.
What Vermont Patients Should Remember
- Ketamine is not approved as a treatment for any substance use disorder.
- The most relevant studies are small, preliminary, and often combine IV ketamine with structured psychological treatment.
- A 2022 alcohol-use-disorder trial found more abstinent days but not a statistically significant reduction in relapse rates.
- Early cocaine-use-disorder research is encouraging but does not establish routine clinical effectiveness.
- Findings from IV research cannot automatically be applied to IM ketamine.
- Ketamine has its own misuse and dependence risks.
- Proven addiction treatments should not be delayed or replaced.
- An individualized evaluation is essential when substance use is part of the clinical picture.
A Careful and Compassionate Path Forward
Recovery is rarely a single decision or a single intervention. It is an ongoing process that may involve biological treatment, psychological work, practical support, repaired relationships, and repeated adjustments over time.
Ketamine is an intriguing area of addiction research, but it is not a shortcut around that process. For selected patients, future research may clarify whether it can complement established care. Today, the most responsible approach is to treat the evidence as emerging, assess risk carefully, and keep proven addiction treatment at the center of the plan.
At Taconic Psychiatry, we approach these conversations without judgment and without guarantees. We want patients to understand what is known, what remains uncertain, and what level of care best supports their safety and recovery.
To discuss co-occurring psychiatric concerns or whether a ketamine evaluation may be appropriate, contact our team to request a consultation. You can also schedule a consultation directly through our online form.
About Adam Pruett, MD, MPH
Adam Pruett, MD, MPH, graduated magna cum laude from Birmingham-Southern College with a BA in German. He completed medical school at the University of Alabama and his psychiatry residency at Emory University, where he served as chief resident at Grady Hospital and helped teach and supervise physicians in training.
Dr. Pruett spent more than 10 years working primarily in inpatient psychiatric settings in Alabama and Vermont. He later completed an immersive, year-long fellowship with the Integrative Psychiatry Institute.
Dr. Pruett co-founded Taconic Psychiatry in Manchester, Vermont, with his colleague Ben Stillman, PsyD. Our practice offers integrative psychiatry, psychotherapy, at-home ketamine protocols, and in-office intramuscular ketamine treatment.
Works Cited
Dakwar, E., Nunes, E. V., Hart, C. L., et al. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. The American Journal of Psychiatry, 176(11), 923–930. doi:10.1176/appi.ajp.2019.18101123
Das, R. K., Gale, G., Walsh, K., et al. (2019). Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nature Communications, 10, 5187. doi:10.1038/s41467-019-13162-w
Grabski, M., McAndrew, A., Lawn, W., et al. (2022). Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder. The American Journal of Psychiatry, 179(2), 152–162. doi:10.1176/appi.ajp.2021.21030277
National Institute on Drug Abuse. (2024). Co-occurring disorders and health conditions.
National Institute on Drug Abuse. (2024). Ketamine.
Substance Abuse and Mental Health Services Administration. (2021). TIP 63: Medications for opioid use disorder.
Vermont Department of Health. (2026). 2025 fatal overdose report.
Medical Disclaimer
The information provided in this blog is for educational purposes only and does not constitute medical advice, diagnosis, addiction treatment, or emergency care. Ketamine is not approved as a treatment for any substance use disorder, and it is not appropriate for everyone. Treatment outcomes vary. Consult qualified psychiatric and addiction-treatment professionals before beginning or changing care.
Taconic Psychiatry does not provide emergency or detoxification services through this article. If someone may be experiencing an overdose, call 911 immediately. For substance-use treatment referrals in the United States, call the SAMHSA National Helpline at 1-800-662-HELP (4357). For an immediate mental health or substance-use crisis, call or text 988.